Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport<sup>®</sup>)

Simonetta‐Moreau, Marion; Picaut, Philippe; Volteau, Magali; Poewe, Werner

doi:10.1111/ene.13800

Cited by 5 publications

(5 citation statements)

References 6 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 27% of the current study indicated that they had a history of difficulties with their mental health, supporting a recent study which found that 23% had a history of clinical diagnosis of mood disorder prior to CD onset and 39% reported having one at any stage (Ndukwe et al, 2020a , 2020b ). With regard to HRQoL, the current cohort reported a CDIP-58 score of 35.83, which is substantially lower than a recent multicentre randomised controlled trial ( M = 59.1; Simonetta-Moreau et al, 2019 ), which suggests that the current group of pwCD experience a higher HRQoL.…”

Section: Discussioncontrasting

confidence: 84%

Illness Perceptions, Coping, Health-Related Quality of Life and Psychological Outcomes in Cervical Dystonia

O’Connor

Hevey

O’Keeffe

2022

J Clin Psychol Med Settings

View full text Add to dashboard Cite

This study examined the predictive ability of the Common-Sense Model to explain psychological outcomes in cervical dystonia, a movement disorder that affects the muscles of the head and neck. Illness Perceptions Questionnaire-Revised, brief COPE, Hospital Anxiety and Depression Scale, Cervical Dystonia Impact Profile and the Post-Traumatic Growth Inventory were completed by 118 people with cervical dystonia. Correlations and hierarchical multiple regression models were conducted. Illness perceptions and coping strategies explained 59% of variance in anxiety, 61% of variance in depression and health-related quality of life and 19% of variance in post-traumatic growth. Illness perceptions and coping strategies are significant factors to consider in terms of psychological adjustment and outcomes in cervical dystonia. Psychological interventions targeting illness perceptions and coping strategies may be beneficial in improving psychological outcomes for people with cervical dystonia.

show abstract

Section: Discussioncontrasting

confidence: 84%

Illness Perceptions, Coping, Health-Related Quality of Life and Psychological Outcomes in Cervical Dystonia

O’Connor

Hevey

O’Keeffe

2022

J Clin Psychol Med Settings

View full text Add to dashboard Cite

show abstract

“…The QoL measure (CIDIP-58), another measure with no pre-defined thresholds, is lower in our patients than in other reports in the literature [23] , [20] , again possibly indicating a milder form of disease. In our correlation analysis, we noted no clear significant correlations between mood, cognitive and motor scores.…”

Section: Discussioncontrasting

confidence: 77%

A comprehensive cognitive analysis of cervical dystonia: A single centre study

Rafee,

Diepman,

McCormack

et al. 2023

Clinical Parkinsonism & Related Disorders

View full text Add to dashboard Cite

“…BoNT-A toxin causes muscle paralysis by inhibiting the peripheral cholinergic nerves from releasing acetycholine which triggers contraction of muscles. Several studies have shown that BoNT-A therapy increases free movement range, alleviates pain and improves quality of life for CD patients [6][7][8][9]. A considerable amount of studies have confirmed that BoNT-A is effective and well-tolerated in patients with CD [3].…”

Section: Introductionmentioning

confidence: 99%

Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

et al. 2020

View full text Add to dashboard Cite

Background: Botulinum neurotoxins type A (BoNT-As) are commonly used treatments for cervical dystonia (CD). Clinical trials have demonstrated the benefits of them in these patients, but data from real-life clinical practice as well as comparative data on the cost and outcome of different BoNT-A formulations are limited. The aim of this study was to compare abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) on their clinical outcomes and drug costs in real-life clinical practice. Methods: This analysis included 356 adult patients with idiopathic CD treated with aboBoNT-A (n = 253) or onaBoNT-A (n = 103) from 38 centres across Europe and Australia (NCT00833196). The clinical outcome measures were treatment responses, changes in TWSTRS scores and changes in health utility scores from baseline to study visit 2 and 3. Health utility score was mapped from the TWSTRS total scale, using a previous publication. Costs included drug cost for France. Results: The aboBoNT-A treated group had 2.06 (95% CI: 1.15 to 3.69) times higher odds of achieving treatment response than the onaBoNT-A treated group. The adjusted mean change in TWSTRS total score from baseline to visit 3 were − 6.42 (95% CI: − 7.52 to − 5.33) for aboBoNT-A and − 3.94 (95% CI: − 5.68 to − 2.2) for onaBoNT-A, with a difference of − 2.48 (95% CI: − 4.57 to − 0.39). The corresponding difference in the adjusted mean change for health utility score was 0.008 (95% CI: 0.001 to 0.014). Mean treatment costs for aboBoNT-A and onaBoNT-A were 314.1 (95% CI: 299.1 to 329.0) and 346.6 (95% CI: 322.9 to 370.4) Euros, respectively. Conclusions: This comparative analysis indicated that treatment with aboBoNT-A may be less costly and lead to improved clinical outcomes when compared with onaBoNT-A, from a French healthcare system perspective. Additional comparative clinical data from larger patient cohorts, as well as more information about cost consequences of an improvement in clinical outcome would be of value to further confirm the findings.

show abstract

Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport^®)

Abstract: Repeat ASI injections are similarly effective to abobotulinumtoxinA in improving patient-reported outcomes of health-related quality of life. Positive correlations were found between TWSTRS total and domain scores and CDIP-58 total and domain scores.

Cited by 5 publications

References 6 publications

Illness Perceptions, Coping, Health-Related Quality of Life and Psychological Outcomes in Cervical Dystonia

Illness Perceptions, Coping, Health-Related Quality of Life and Psychological Outcomes in Cervical Dystonia

A comprehensive cognitive analysis of cervical dystonia: A single centre study

Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Contact Info

Product

Resources

About

Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport®)

Abstract: Repeat ASI injections are similarly effective to abobotulinumtoxinA in improving patient-reported outcomes of health-related quality of life. Positive correlations were found between TWSTRS total and domain scores and CDIP-58 total and domain scores.

Cited by 5 publications

References 6 publications

Illness Perceptions, Coping, Health-Related Quality of Life and Psychological Outcomes in Cervical Dystonia

Illness Perceptions, Coping, Health-Related Quality of Life and Psychological Outcomes in Cervical Dystonia

A comprehensive cognitive analysis of cervical dystonia: A single centre study

Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Contact Info

Product

Resources

About

Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport^®)